nintedanib
Boehringer’s nintedanib approved in Europe for systemic sclerosis-associated interstitial lung disease
April 22, 2020Research and Development, Sales and Marketing Boehringer Ingelheim, EU, nintedanib, pharma
The European Commission has moved to authorise Boehringer Ingelheim’s nintedanib in Europe for the treatment of systemic sclerosis-associated interstitial lung …
Boehringer widens IPF drug’s reach
May 18, 2015Sales and Marketing Boehringer, Esbriet, ats, brett wells, nintedanib, ofev
Boehringer Ingelheim has highlighted new data for its idiopathic pulmonary fibrosis (IPF) treatment Ofev in a Phase II study on …
Boehringer assures future growth following sales drop
April 23, 2015Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results
Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …
Boehringer gains EU approval for Ofev
January 19, 2015Sales and Marketing Boehringer, Esbriet, IPF, InterMune, ingelheim, nintedanib, ofev
The European Commission has approved Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis (IPF). The approval follows the …
Boehringer’s lung cancer drug Vargatef sees EU approval
November 28, 2014Sales and Marketing Boehringer, EU, Europe, IPF, NSCLC, lung cancer, nintedanib, ofev, vargatef
Boehringer Ingelheim’s nintedanib has received its second nod in Europe this month with the European Commission approving it for the …
CHMP nods several drugs through
November 24, 2014Sales and Marketing Boehringer, CHMP, EMA, Esbriet, FDA, Sanofi, nintedanib, ofev
Ten new medicines have been recommended for approval by the EMA’s Committee for Medicinal Products for Human Use (CHMP), among …
Boehringer seeks more indications for IPF drug
October 22, 2014Research and Development, Sales and Marketing Boehringer, IPF, NSCLC, colectoral, crc, nintedanib, ofev
Boehringer Ingelheim’s nintedanib has entered Phase III studies for the treatment of colorectal cancer (CRC), which could add to the …
Boehringer’s lung cancer drug gets EMA nod
September 29, 2014Sales and Marketing Boehringer, IPF, docetaxel, ingelheim, lung cancer, nintedanib
The EMA has issued a positive opinion for the approval of Boehringer Ingelheim’s nintedanib in combination with docetaxel for the …
EMA accepts Boehringer IPF drug
June 6, 2014Sales and Marketing Boehringer, EMA, IPF, inpulsis, lung, nintedanib
Boehringer Ingelheim has moved a step closer to getting its investigational treatment nintedanib approved in Europe for a potentially fatal …
Boehringer cancer drug impresses
October 1, 2013Research and Development, Sales and Marketing Boehringer, NSCLC, nintedanib
Boehringer Ingelheim has shown off its impressive oncology treatment nintedanib at the European Cancer Congress (ECC) in Amsterdam. The oral triple …
Latest content
FibroFind appoints Lee Borthwick as CEO
